Radiofrequency Ablation Systems Market Size, Share and Global Trend By Product (Unipolar Radiofrequency Ablation Systems, Bipolar Radiofrequency Ablation Systems), By Application (Pain Management, Oncology), By End User (Hospitals, Clinics, Ambulatory Surgery Centres), Regional Forecast, 2024-2032

According to results of clinical research published in 2017, Radiofrequency (RF) Ablation Therapies increase the chances of cancer curing by an estimated 40.0%, and additionally, an estimated 60.0% of cancer patients undergo radiotherapy across the globe. Radiofrequency Ablation is a non-surgical method used to destroy tissues responsible for cancer and also to destroy nerves which are sending pain signals to the brain.

Radiofrequency ablation systems utilize heat to kill the cancer cells as well as to interrupt the pain signals to the brain. The procedure is most commonly used in chronic pain, cardiac procedures and elimination of tumors. Radiofrequency ablation system is completely safe and has high potency as compared to surgical procedures. 

The gradual shift of surgical procedures from conventional to minimally invasive is expected to boost the growth of the Global Radiofrequency Ablation Systems Market during the forecast period. Moreover, technological advancements in radiofrequency procedures are serving better treatment outcomes, owing to which radiofrequency ablation systems are expected to witness higher adoption in forthcoming years. In 2017, Medtronic’s OsteoCool RF ablation system got FDA approval. The system is specifically designed for the treatment of metastatic bone tumors. 

Certain factors such as lower accessibility in emerging nations and higher maintenance cost are expected to hamper the growth of the global radiofrequency ablation systems market during the forecast period.

 Key Players Covered 

Some of the major companies that are present in the global radiofrequency ablation systems market are Abbott, AngioDynamics, Boston Scientific Corporation, Johnson & Johnson Services, Inc., Medtronic, Stryker, Gynesonics, Inc., RF MEDICAL, AtriCure, Inc., ENDO-FLEX GmbH, Bramsys Indústria e Comércio Ltda., RZ Medizintechnik, Sutter Medizintechnik GmbH, Hologic Inc., and others. 

SEGMENTATION  

Among the segmentation, oncology in the application segment is projected to hold a considerable share of the global radiofrequency ablation systems market due to higher adoption of radiofrequency ablation systems for cancer treatment in developed as well as developing countries. 

Key Insights 

• Regulatory scenario for key countries
• Reimbursement scenario for key countries
• Recent industry developments such as partnerships, mergers, and acquisitions
• Key performance indicators for global radiofrequency ablation systems market 

Regional Analysis 

North America is anticipated to hold a considerable share of the global radiofrequency ablation systems market owing to increasing adoption of non-invasive surgical techniques, the rise in prevalence of chronic diseases such as cancer, cardiac arrest, and chronic back & neck pain. Asia Pacific holds potential for radiofrequency ablation systems owing to the rise in prevalence of chronic diseases and increasing need for safe surgical methods. According to World Health Organization, in 2016, approximately 30 countries in Africa and Asia Pacific region had a shortfall of radiofrequency ablation systems, which indicates the huge potential for these systems in these regions and is expected to drive the growth of radiofrequency ablation systems in the forecast period.  

Key Industry Developments

• In August 2018, Gynesonics, Inc. got FDA approval for their new Sonata Sonography-Guided Transcervical Fibroid Ablation System. 
• In January 2019, Venclose, Inc. and Viant agreed upon strategic partnership to design and develop Venclose’s next generation VENCLOSE RF Ablation Catheter System.
• In February 2019, Medtronic launched its new radiofrequency ablation system, Accurian. The new system is configured with hardware, innovative software for temperature control and quad-core processor with aim to offer efficiency in standard, pulsed and enhanced procedures.
•  In February 2019, J&J’s Biosense Webster initiated the trail for its IDE- Cleared Qdot Micro radiofrequency ablation system in order to treat symptomatic drug-refractory paroxysmal atrial fibrillation.